BCBelinda Cruse

Belinda Cruse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Belinda Cruse has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exteroceptive Reflexes in Stiff Person Syndrome, Other Neurological Conditions and Healthy Controls

    by Belinda Cruse, Duncan Wilson, Hugo Morales Briceno, Pamela Garcia, Victor Zhang, Jessica Qiu, Tomas Kalincik, Neil Mahant, Victor Shue Chung Fung

    Background: Stiff person syndrome (SPS) is a rare disabling neurological condition with overlapping symptomatology with more common neurological conditions. Exaggerated exteroceptive reflex mechanisms are thought to play a role in its pathophysiology. Objectives: We aim to describe the results of neurophysiological exteroceptive reflex testing in subjects with SPS, healthy controls, and other neurological conditions causing axial and lower limb muscle stiffness, pain and spasms. Methods: We performed a prospective cohort study, of 59 participants with a variety of neurological conditions, healthy controls and 11 with SPS. Retrospective data from participants with SPS who had prior exteroceptive reflex testing performed in an equivalent manner were also included in our analysis. Reflex responses were recorded by simultaneous surface electromyography (sEMG) of axial and lower limb muscles following repeated stimulation of the median and tibial nerves. Results: Latencies following repeated activation of median and tibial nerves demonstrated a moderate to very strong correlation at most EMG recording sites within individuals. Using a mixed effects logistic model shorter mean latencies were observed in those with Parkinson's disease, healthy controls, low back pain and serotonergic/noradrenergic antidepressant use compared with SPS following initial stimulation and when the shortest latency at each site within individual participants were analyzed. No study group differed significantly from SPS in the duration of responses following stimulation nor the presence or absence of after‐bursts. Conclusion: The use of exteroceptive testing as performed in this study did not differentiate SPS from other neurological conditions or healthy controls.

  • Open Access

    Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy

    by Lynette Kiers, Belinda Cruse

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, immune-mediated neuropathy of the peripheral nerves and nerve roots. CIDP is unlikely to be a discrete disease entity, but rather a spectrum of related conditions, in which cell-mediated and humoral mechanisms act synergistically to cause damage to peripheral nerves. The 2021 guideline of the European Academy of Neurology/Peripheral Nerve Society on the diagnosis and treatment of CIDP has modified the CIDP spectrum to include typical CIDP and four well-defined CIDP variants. Patients with CIDP usually respond well to immunoglobulin therapy, steroids or plasmapheresis; however, 20–30% do not respond well, and approximately 15% remain refractory to all treatment modalities. Rituximab, mycophenolate mofetil and cyclophosphamide are of therapeutic benefit for some of these patients. Patients with some CIDP variants respond less well to immunotherapy, suggesting a difference in the pathogenic mechanisms underlying these variants. Potential novel treatments trialled in CIDP, targeting functionally relevant disease mechanisms, include neonatal Fc receptor blockers and complement inhibitors. These new treatment approaches are needed to optimise disease outcomes in refractory patients, and as an alternative for patients with suboptimal response requiring high doses or experiencing side effects from first-line therapies. Increasing the therapeutic options for patients with CIDP, particularly for refractory patients, highlights the need for more accurate diagnosis of typical CIDP and CIDP variants, objective evidence of treatment response and the need for reliable clinical biomarkers.


  • Exploring Factors That Prolong the Diagnosis of Myasthenia Gravis

    by Minh Nguyen, Meaghan Clough, Belinda Cruse, Anneke van der Walt, Joanne Fielding, Owen B. White

    Myasthenia gravis (MG) is a condition with significant phenotypic variability, posing a diagnostic challenge to many clinicians worldwide. Prolonged diagnosis can lead to reduced remission rates and morbidity. This study aimed to identify factors leading to a longer time to diagnosis in MG that could be addressed in future to optimize diagnosis time. One hundred and ten patients from 3 institutions in Melbourne, Australia, were included in this retrospective cohort study. Demographic and clinical data were collected for these patients over the first 5 years from diagnosis and at 10 years. Nonparametric statistical analysis was used to identify factors contributing to a longer diagnosis time. The median time for MG diagnosis was 102 (345) days. 90% of patients were diagnosed before 1 year. Female patients took longer than male patients to be diagnosed (p = 0.013). The time taken for first presentation after symptom onset contributed most to diagnosis time (median 17 [141] days), with female patients and not working as contributory factors. Neurology referral took longer if patients had diplopia (p = 0.022), respiratory (p = 0.026) symptoms, or saw an ophthalmologist first (p < 0.001). Outpatient management compared with inpatient was associated with a longer time to be seen by a neurologist from referral (p < 0.001), for the first diagnostic result to return (p = 0.001), and for the result to be reviewed (p < 0.001). Ocular MG had a median greater time to neurologist review than generalized MG (median 5 [25] days vs 1 [13] days, p = 0.035). Electrophysiology tests took longer for outpatients than inpatients (median 21 [35] days vs 2 [8] days, p < 0.001). Outpatients were also started on treatment later than inpatients (p < 0.001). There was no association of MG severity, ethnicity, age, medical and ocular comorbidities, and public or private health service on diagnosis time. There was also no impact of time to diagnosis on Myasthenia Gravis Foundation of America outcomes, number of follow-ups or hospitalizations, or prevalence of treatments used. This study is limited by low patient numbers and its retrospective nature. This study identified several factors that can contribute to a prolonged diagnosis time of MG. Patient and clinician education about MG and outpatient diagnostic efficiency needs emphasis. Further studies are also needed to explore the delayed presentation time of women and nonworking patients in MG.


  • Open Access

    Efficacy of botulinum toxin type a in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study

    by Belinda Cruse, Thanuja Dharmadasa, Elise White, Callum Hollis, Andrew Evans, Sifat Sharmin, Tomas Kalincik, Lynette Kiers

    Background Intramuscular injections of botulinum toxin A (BTX-A) have been used in the treatment of sleep bruxism (SB) however controlled trials are limited and the optimal injection strategy and dose is not known. Methods This double-blind, randomised, placebo-controlled, cross-over study evaluated the efficacy and safety of BTX-A in participants with SB. Average bruxism events per hour of sleep (Bruxism Index, BI) was calculated using surface electromyography. Participants with BI >5 were included and randomised by order of injection (active or placebo with the opposite 20 weeks later) and into one of three differing treatment groups: bilateral masseter (60 units(U)), bilateral masseter and temporalis (90U) and bilateral masseter, temporalis and medial pterygoid muscles (120U). Change in BI and subjective measures of headache, pain, and bruxism at 4 and 12 weeks was calculated following intervention, and differences between treatment groups analysed. Results 41 participants were recruited, 35 randomised and data from 22 participants (14 female) were analysed. BI was significantly lower at 4 weeks after active treatment when compared with placebo (mean=−1.66, p=0.003), not sustained at 12 weeks. The difference was greater with higher doses injected and among those with greater baseline BI. There was no difference in subjective measures at any time point. Five participants injected had mild, transient side effects. Discussion Targeted BTX-A injection is a safe and effective treatment for SB. A greater benefit may be achieved by administering BTX-A into more muscles and at higher total doses and among those with higher baseline BI. Trial registration number ACTRN12618001430224.


  • Characterization of sedation and anesthesia complications in patients with alternating hemiplegia of childhood

    by Lauren E. Parker, Keri Wallace, Arthur Thevathasan, Emily Funk, Milton Pratt, Julie Thamby, Linh Tran, Lyndsey Prange, Julie Uchitel, April Boggs, et al.


  • Open Access

    Oromandibular parafunction in chronic graft‐versus‐host disease: novel association and treatment approach

    by Purwa Joshi, Lynette Kiers, Andrew Evans, David Ritchie, Jeff Szer, Belinda Cruse

    Chronic graft‐versus‐host disease (cGVHD) complicating allogeneic haemopoietic stem cell transplantation rarely involves the nervous system; oromandibular parafunction has not been previously reported. We describe five patients with cGVHD, presenting with bruxism, limitation of mouth opening, jaw locking, pain and masseter hypertrophy. Pathophysiological mechanisms are discussed. Targeted botulinum toxin injections were an effective treatment with minimal side‐effects.


  • Nitrous oxide‐induced neurological disorders: an increasing public health concern

    by Jessica Redmond, Belinda Cruse, Lynette Kiers

    Background: Neurological presentations resulting from nitrous oxide (N2O) abuse are increasing in Australia and worldwide. Despite known neuropsychiatric sequelae, N2O canisters remain readily available and its use unregulated.Aims: To examine the demographics, clinical and electrophysiological findings of patients presenting with neurological complications of N2O abuse, and thus inform clinicians and public health decision‐makers of the significant public health concerns of this increasing practice.Methods: Consecutive patients presenting to a tertiary referral metropolitan hospital were included in this series. Patients were identified by a search of discharge summaries of patients admitted with acute or subacute neuropathy or myelopathy and a history of N2O abuse, and from the electrophysiology database.Results: Thirteen patients were identified, most presenting with subacute paraesthesia, sensory ataxia and lower limb weakness. Eleven had low serum vitamin B12. Spinal magnetic resonance imaging was consistent with subacute combined degeneration in eight. Nerve conduction studies revealed a motor or sensorimotor axonal neuropathy (three with motor predominance). There was a bimodal demographic distribution consisting of socially isolated, international university students and local residents with a history of mental illness and polydrug abuse.Conclusions: Recreational N2O use is an emerging health problem in Australia. International university students and patients with pre‐existing mental illness or polydrug use appear to be at increased risk. A severe motor neuropathy may emerge following vitamin B12 replacement. Public health measures are required to limit the availability of N2O and to educate adolescents and young adults about the potential for significant harm.